Jan. 17, 2025
| Today’s news and insights for biopharma leaders
|
NOTE FROM THE EDITOR
BioPharma Dive will take a publishing break Monday for Martin Luther King Jr. Day. We’ll be back with our usual programming on Tuesday, Jan. 21.
We hope you’ve enjoyed our coverage of the J.P. Morgan Healthcare Conference over the past week. If you missed, you can read our reporters’ daily dispatches here, here and here. And be sure to check out our deep dive below!
|
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
|
UPDATED
Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health policy acts.
|
UPDATED
Patents protecting Ibrance and Xtandi, two of the next 15 drugs Medicare selected for price talks, are set to expire by 2027, when any negotiated discount would take effect.
|
How clinical services organizations are overcoming challenges in the APAC market.
|
News roundup
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
|
Deep Dive
Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors and executives interviewed by BioPharma Dive at the J.P. Morgan Healthcare Conference.
|
|
Read this playbook to learn how APPs influence treatment plans and how brands can connect with them to enhance patient journeys and improve results.
|
|
From Our Library
Playbook
Custom content for Avant Healthcare
|
| 
